Clinical Trial Update: Stereotactic Body Radiotherapy (SBRT) With Concurrent Boost for Low- and Intermediate-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating stereotactic body radiotherapy with concurrent boost for low- and intermediate-risk prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Rocky Mountain Cancer Centers | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN